Paul has more than 15 years of industry experience in translational research and early clinical development. Paul holds an MBiochem from the University of Oxford and a PhD from University College London. After this, Paul spent 12 years at GlaxoSmithKline, transitioning from laboratory biomarker research, through experimental medicine study leadership, to leading global project teams as Director of Discovery Medicine in the Neurology TA. Paul then worked as a clinical science director at ONO Pharma UK, leading clinical development of multiple early phase assets across a variety of indications including inflammatory pain, portal hypertension, whilst driving translational strategies for pre-clinical programs. 

In 2016, Paul joined Mission Therapeutics to lead their USP30 inhibitor program, which is in development for Parkinson’s disease and other acute and chronic degenerative conditions. Paul recently transitioned from leading clinical development within Mission to becoming Chief Scientific Officer, accountable for Mission’s internal pipeline of discovery programs.